Kings Path Partners’s Eli Lilly LLY Stock Holding History

Kings Path Partners’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-891	Closed	-$695K	–	328
2025 Q2	$695K	Buy	+891	New	+$692K	0.28%	44

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Kings Path Partners's LLY Position: Q3 2025 in Review

Kings Path Partners sold out of Eli Lilly (LLY) in Q3 2025, closing a stake of 891 shares — an estimated $695K sold.

Kings Path Partners first reported a position in LLY in Q2 2025 and held it in 1 quarter. The position peaked at $695K in Q2 2025. 3,897 funds tracked by Wall St. Rank hold LLY as of Q3 2025.

Kings Path Partners reported no remaining Eli Lilly position as of Q3 2025 after selling out during the quarter.
Kings Path Partners sold 891 Eli Lilly shares in Q3 2025, an estimated $695K.
Kings Path Partners first reported a position in Eli Lilly in Q2 2025 and held it in 1 quarter.
Kings Path Partners's Eli Lilly position peaked at $695K in Q2 2025.
3,897 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2025.

Based on Kings Path Partners's 13F filing for Q3 2025, filed 13 Jul 2026.